Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations-Reference-Cited by-同舟云学术

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Published:2015-05 Issue:5 Volume:10 Page:793-799
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Chiu Chao-Hua,Yang Cheng-Ta,Shih Jin-Yuan,Huang Ming-Shyan,Su Wu-Chou,Lai Ruay-Sheng,Wang Chin-Chou,Hsiao Shih-Hsin,Lin Yu-Ching,Ho Ching-Liang,Hsia Te-Chun,Wu Ming-Fang,Lai Chun-Liang,Lee Kang-Yun,Lin Chih-Bin,Yu-Wung Yeh Diana,Chuang Chi-Yuan,Chang Fu-Kang,Tsai Chun-Ming,Perng Reury-Perng,Chih-Hsin Yang James

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart;Travis,2004

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review;Heliyon;2024-08

2. Integrated multi-omics profiling reveals a clinically relevant molecular feature and potential therapeutic target on phyllodes tumors of breast;Translational Oncology;2024-08

3. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review;Journal of Thoracic Oncology;2024-07

4. Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC);Cancers;2024-06-27

5. Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunities;2024-05-31